Highlights include pooled safety findings from Paratek's Phase 3 studies in community acquired pneumonia (CABP) and acute bacterial skin and skin structure infection (ABSSSI), as well as additional ...
Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF. Check out ...
GSK has completed its 950 million dollar acquisition of 35Pharma, adding HS235, a promising pulmonary hypertension therapy, ...
RAPIBLYK (R) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker administered intravenously in a monitored hospital setting. Its pharmacological profile allows for rapid onset and ...
Cautionary Language Concerning Forward-Looking Statements ...
Finance News; GSK completes purchase of Canada's 35Pharma for USD950 million; GSK completes purchase of Canada's 35Pharma for USD950 million ...
Guest writer Genesis “Gigi” Gonzalez says that, while living with PH, there are moments when she wants to ask, "Why did this ...
Glasgow Times on MSN
New cancer treatments approved for NHS Scotland in major medicine update
Scottish Medicines Consortium approves new NHS Scotland drugs for lung cancer, leukaemia, cervical cancer, pulmonary ...
On Monday, the Scottish Medicines Consortium (SMC) said it had accepted five out of six newly-licensed medicines under ...
A recent study published in CHEST found that treatment-naïve adults with obesity-hypoventilation syndrome receiving a ...
Cardiology experts from UCSF Health presented new research and clinical findings at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo in New Orleans, March 28 to 30. The ...
Scientists have created a new "molecular map" uncovering how an important human receptor involved in blood clotting and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results